Insulin-Like Growth Factor-I in the Parenterally Fed Low Birth Weight Infant

Saini, J.; Morgan, Jane; Teale, J D; Kovar, I Z

doi:10.1159/000177525

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been proposed as an index of nutritional status in both humans and ani mals, including studies of intrauterine nutri tion and growth [15,16]. The serum concen tration of somatomedin C is thought to reflect nutrient intake and overall nutritional status in low-birth-weight infants [15], Cassio et al [17] found that day of life and birth weight had significant influences on somatomedin C levels, but that gestational age had no signifi cant effect. These authors also noted that this hormone was reduced during the early neona tal period with a tendency to rise over time.…”

Section: Discussionmentioning

confidence: 99%

Early Minimal Feedings Promote Growth in Critically III Premature Infants

Harvey-Wilkes

Engle

et al. 1995

Neonatology

View full text Add to dashboard Cite

Critically ill premature infants requiring mechanical ventilation and an umbilical artery catheter usually do not receive enteral feedings during the acute phase of their illness. We studied the safety and benefit of early minimal enteral feedings during this time in a prospective, controlled, and randomized study. Twenty-nine infants were randomly assigned to receive only standard intravenous fluid and nutrition (nothing per OS, NPO group; n = 13), or in addition to receive small-volume hypocaloric continuous feedings (1 ml/kg/h), beginning at 24 h of age (early-feeding group; n = 16). Standard enteral feedings were begun in both groups at the resolution of the acute phase of the illness and advanced by protocol. The two groups were of comparable birth weight, gestational age, and Apgar scores. There were no significant differences in the episodes of feeding intolerance. Two infants in the NPO group developed clinical signs of necrotizing enterocolitis. Serum diamine oxidase and somatomedin C were measured weekly until 30-60 days of age and were not different between the two groups. The early-feeding group required fewer days to reach 120 ml/kg/day enteral intake (early-feeding group 10 + 3 days, NPO group 13 ± 4 days; p < 0.05). On day 30 of life the early-feeding group was 223 ± 125 g above birth weight, while the NPO group was 95 ± 161 g above birth weight (p < 0.05). The average intake (kcal/kg/day) from day 6 to day 30 was not different between the two groups. We conclude that early minimal feedings in critically ill very-low-birth-weight infants requiring mechanical ventilation are well tolerated and result in reduced time to reach 120 ml/kg/day of enteral feeding and in a greater weight gain by day 30 of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Early Minimal Feedings Promote Growth in Critically III Premature Infants

Harvey-Wilkes

Engle

et al. 1995

Neonatology

View full text Add to dashboard Cite

show abstract

“…There are two other longitudinal reports of circulating levels of IGF-I in preterm infants, each of relatively short duration (18,29). One (29) reported a decline in plasma IGF-I levels in nine sick, parenterally fed preterm infants between 6 and 28 d of age.…”

Section: Discussion Table 4 Correlation Of Individual Concentrationsmentioning

confidence: 99%

Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein 3 during the First Year in Term and Preterm Infants

et al. 1995

View full text Add to dashboard Cite

Plasma IGF-I and IGF-binding protein 3 (IGFBP-3) were determined by radioimmunoassay in term infants (n = 51) at 0, 2,4, 6, and 12 mo and preterm infants (n = 51) at -3 (28.4 wk postconceptional age), -2, -1.5, -1,0,2,4,6,9, and 12 rna from expected term. The effects of gestational age at birth (term or preterm) and study age were determined by repeated measures analysis of variance and Fisher's least squares difference. In preterm infants, IGF-I increased between -3 and 2 mo from 0.75 to 10.4 nM, decreased between 2 and 9 mo to 7.3 nM, and increased again between 9 and 12 mo to 10.1 nM (p < 0.0001), whereas IGFBP-3 increased relatively little from -3 to 0 rna (14.2 to 30.2 nM, p < 0.05) and plateaued from 2 to 12 mo (49.8 to 62.3 nM). At 0 rna, IGF-I and IGFBP-3 were the same in term and preterm infants, but preterm infants had higher IGF-I from 2 IGF mediate the growth-promoting actions of growth hormone in regulating the proliferation and differentiation of different cell types (1). These polypeptides which are structurally homologous to insulin also exert insulin-like metabolic effects. Both these effects are mediated through target cell surface receptors (2). Most tissues in the body produce IGF, and they are present in serum mostly bound to specific high molecular weight binding proteins (3). Of the six IGFBP that have been identified so far, IGFBP-3 is the major form present in the serum (1, 2) and demonstrates a high affinity for both IGF-I and IGF-II. IGFBP-3 can exhibit either an inhibitory (4) or a potentiating (5) effect on IGF-I bioactivity in vitro, depending on its ability to alter the equilibrium between IGF-I and its receptor (5).

show abstract